retatrutide phase 3 trials Eli Lilly's clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments retatrutide phase 3 #obesity #osteoarthritis

Because they significantly alter your metabolic rate and digestive speed, their impact on other hormonal systemsespecially the thyroidis a topic of significant clinical interest

Following the standard retatrutide dose chart , most protocols begin at lower doses and increase gradually

Its accepting that they need ongoing treatment

References 1

In the clinical trials of retatrutide conducted so far, one of the key observations has been that while side effects were relatively common, they were overwhelmingly mild to moderate in intensity

doi: 10.1161/atv.0000615456.97862.30 20 HendartoH.InoguchiT.MaedaY.IkedaN.ZhengJ.TakeiR.et al